![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBiQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--9100a2acb36f24bc0b0dc46e1951c6853af0442e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Arrakis-Logo-horizontal-RGB_small.jpg)
Arrakis Therapeutics
Arrakis Therapeutics is developing a platform for targeting RNA with small molecules for neurology, oncology and rare disease.
Website
arrakistx.comPartner
Colleen CuffaroInvestment
Series A
Arrakis Therapeutics is developing a platform for targeting RNA with small molecules for neurology, oncology and rare disease.
Series A